📊 CYCN Key Takeaways
Is Cyclerion Therapeutics, Inc. (CYCN) a Good Investment?
Cyclerion Therapeutics exhibits severe operational deterioration with -$5.0M operating losses against only $2.1M in revenue, indicating a pre-commercial stage pharmaceutical company. With negative operating cash flow of -$3.3M annually and only $3.2M in cash, the company faces approximately 1 year of runway before requiring dilutive capital raise, placing shareholders at significant financing risk.
Cyclerion Therapeutics shows very weak fundamentals, with minimal revenue, deeply negative operating and net margins, and negative free cash flow that indicates the business is not self-sustaining. While the balance sheet is currently supported by strong liquidity and no meaningful leverage, the small cash base relative to ongoing losses creates substantial funding and dilution risk unless operating performance improves materially.
Why Buy Cyclerion Therapeutics, Inc. Stock? CYCN Key Strengths
- Strong liquidity position with 5.15x current and quick ratios provides near-term operational flexibility
- Zero long-term debt eliminates refinancing risk and preserves capital raising capacity
- Positive stockholders' equity of $9.1M maintains viable balance sheet structure
- Strong near-term liquidity with current and quick ratios of 5.78x
- No meaningful debt burden, reducing balance-sheet stress
- Positive stockholders' equity of $9.54M provides some financial cushion
CYCN Stock Risks: Cyclerion Therapeutics, Inc. Investment Risks
- Severe cash burn of $3.3M annually with minimal cash reserves creates critical funding timeline
- Revenue of $2.1M is insufficient to support operating expenses, indicating failed commercialization or pre-launch development stage
- Imminent need for dilutive capital raise will significantly increase shareholder dilution
- Extremely weak profitability, with operating margin of -394.2% and net margin of -260.2%
- Negative operating cash flow and free cash flow indicate continuing cash burn
- Low revenue base of $1.05M suggests limited commercial scale and poor growth quality
Key Metrics to Watch
- Quarterly cash burn trend and remaining cash runway in months
- Revenue growth acceleration or new product commercialization milestones
- Capital raise announcements with dilution terms and use of proceeds
- Quarterly operating cash burn relative to cash and equivalents
- Revenue growth and improvement in operating loss margin
Cyclerion Therapeutics, Inc. (CYCN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.15x current ratio provides a solid financial cushion.
CYCN Profit Margin, ROE & Profitability Analysis
CYCN vs Healthcare Sector: How Cyclerion Therapeutics, Inc. Compares
How Cyclerion Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cyclerion Therapeutics, Inc. Stock Overvalued? CYCN Valuation Analysis 2026
Based on fundamental analysis, Cyclerion Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cyclerion Therapeutics, Inc. Balance Sheet: CYCN Debt, Cash & Liquidity
CYCN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Cyclerion Therapeutics, Inc.'s revenue has declined by 47% over the 5-year period, indicating business contraction. The most recent EPS of $-1.21 indicates the company is currently unprofitable.
CYCN Revenue Growth, EPS Growth & YoY Performance
CYCN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $194.0K | -$324.0K | $-0.29 |
| Q2 2025 | N/A | -$324.0K | $-0.11 |
| Q1 2025 | N/A | -$1.4M | $-0.56 |
| Q3 2024 | N/A | -$723.0K | $-0.29 |
| Q3 2023 | N/A | -$3.6M | $-1.55 |
| Q2 2023 | N/A | -$4.2M | $-1.83 |
| Q1 2023 | N/A | -$7.0M | $-0.16 |
| Q3 2022 | N/A | -$10.5M | $-0.24 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Cyclerion Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
CYCN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cyclerion Therapeutics, Inc. (CIK: 0001755237)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CYCN
What is the AI rating for CYCN?
Cyclerion Therapeutics, Inc. (CYCN) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (STRONG SELL) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CYCN's key strengths?
Claude: Strong liquidity position with 5.15x current and quick ratios provides near-term operational flexibility. Zero long-term debt eliminates refinancing risk and preserves capital raising capacity. ChatGPT: Strong near-term liquidity with current and quick ratios of 5.78x. No meaningful debt burden, reducing balance-sheet stress.
What are the risks of investing in CYCN?
Claude: Severe cash burn of $3.3M annually with minimal cash reserves creates critical funding timeline. Revenue of $2.1M is insufficient to support operating expenses, indicating failed commercialization or pre-launch development stage. ChatGPT: Extremely weak profitability, with operating margin of -394.2% and net margin of -260.2%. Negative operating cash flow and free cash flow indicate continuing cash burn.
What is CYCN's revenue and growth?
Cyclerion Therapeutics, Inc. reported revenue of $2.1M.
Does CYCN pay dividends?
Cyclerion Therapeutics, Inc. does not currently pay dividends.
Where can I find CYCN SEC filings?
Official SEC filings for Cyclerion Therapeutics, Inc. (CIK: 0001755237) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CYCN's EPS?
Cyclerion Therapeutics, Inc. has a diluted EPS of $-1.11.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CYCN a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Cyclerion Therapeutics, Inc. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CYCN stock overvalued or undervalued?
Valuation metrics for CYCN: ROE of -38.8% (sector avg: 15%), net margin of -170.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CYCN stock in 2026?
Our dual AI analysis gives Cyclerion Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CYCN's free cash flow?
Cyclerion Therapeutics, Inc.'s operating cash flow is $-3.3M, with capital expenditures of $0.0. FCF margin is -159.8%.
How does CYCN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -170.1% (avg: 12%), ROE -38.8% (avg: 15%), current ratio 5.15 (avg: 2).